Top 5 drugs in the pipeline

September 22, 2020

Some of the top medications were approved this summer, while others are awaiting FDA approval.

Sandoz to supply critical generic injectable meds

July 14, 2020

The pharma maker is partnering with the nonprofit Civica Rx to help reduce shortages in hospitals.

Popular HIV-1 med successful, particularly in order adults

July 07, 2020

Gilead will present new data on virologic suppression in adults 65 years and older at AIDS 2020: Virtual this week.

Major Metformin recalls underway

June 08, 2020

Five pharma markers are recalling the diabetes medication due to the presence of a carcinogenic ingredient.

Express Scripts Report: Top Drug Classes Driving Spending Growth

February 25, 2020

Express Scripts’ annual Drug Trend Report highlights top contributors to prescription drug spending in 2019.

More Ranitidine recalled, plus another big drug recall

January 10, 2020

Major depression drug recalled over wrong dosage.

Pfizer slashes prices as most pharma makers hike prices in new year

January 03, 2020

Pfizer bucks the trend with as high as 98.5% price cuts.

FDA clears first-in-class migraine drug

January 03, 2020

Approval of Ubrelvy follows several new migraine drugs.

Gilead snags approval for second HIV-1 prevention drug

October 07, 2019

New HIV prevention drug not indicated for women.

FDA approval given for new drug to treat obesity

September 15, 2014

FDA has approved a combination of the generic drugs naltrexone and bupropion (Contrave) for chronic weight management in obese adults (body mass index [BMI] >30 kg/m2). This combination agent has also been approved for use in those patients who are overweight (BMI >27 kg/m2) and have at least one weight-related comorbid condition such as diabetes, hypertension, or dyslipidemia.

Study: Hep C drugs could increase Medicare Part D spending in 2015

August 12, 2014

The federal government’s cost for Medicare Part D will increase between $2.9 billion and $5.8 billion if we see 15% to 30% of hepatitis C (HCV)-infected beneficiaries receive treatment in 2015 and the cost of treatment averages $84,000, according to a new study by Milliman.

Age restriction on emergency contraception lifted

April 10, 2013

On April 5, a US District Court judge ruled that the emergency contraception (EC) pill Plan B One-Step must be made available over-the-counter to all girls and women, regardless of their age. This ruling, made by Judge Edward R. Korman, was in response to a 2011 move by Health and Human Services Secretary Kathleen Sebelius.

Judge orders FDA to make emergency contraceptive available without prescription for all ages

April 05, 2013

A New York federal judge has struck down the restrictions on levonorgestrel-based emergency contraceptives and ordered the FDA to make the drugs available without a prescription and without point-of-sale or age restrictions within 30 days, according to an April 4th memorandum and order

New Jersey compounding pharmacy recalls all products, fearing mold contamination

March 18, 2013

Med Prep Consulting, Inc., a compounding pharmacy in Tinton Falls, NJ, is voluntarily recalling all lots of compounded products from its facility for fear of mold contamination, according to an FDA press release.

Survey reveals healthcare provider trust in OTC medications

March 07, 2013

Almost 98% of primary care physicians (PCPs), nurse practitioners, and pharmacists trust and recommend over-the-counter (OTC) medicines to their patients, according to a new survey released by the Consumer Healthcare Products Association (CHPA).

What to do about multidrug-resistant gonorrhea

February 19, 2013

Gonorrhea, caused by the bacterium, Neisseria gonorrhoeae, continues to be a major US public health problem in terms of its prevalence as well as the lack of effective treatments available.

Med school gift restriction policies linked to subsequent prescribing behavior

February 11, 2013

Physicians who attended a medical school with an active gift restriction policy were subsequently less like to prescribe newly marketed psychotropic medications over older, cheaper alternatives, according to a study published in the January 2013 issue of BMJ.

FDA warns company over flu inhaler

January 31, 2013

FDA and the Federal Trade Commission (FTC) issued a warning letter to Flu and Cold Defense LLC (Boca Raton, Fla.) for making misleading, unproven claims about its GermBullet inhaler, and said the company has been marketing an untested inhaled formula as a flu remedy in violation of drug safety regulations.

FDA approves Botox to treat overactive bladder

January 21, 2013

FDA expanded the approved use onabotulinumtoxinA (Botox, Allergan) to treat adults with overactive bladder (OAB) who cannot use or do not adequately respond to a class of medications known as anticholinergics